Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)

Yang et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69de96fb7702a00918b0bda1 — DOI: https://doi.org/10.1136/jitc-2021-003790

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. The role of Epstein–Barr virus in epithelial malignancies· 2014 · 340 citations
2. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma· 2015 · 151 citations
3. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology· 2020 · 1,358 citations
4. Mutant MHC class II epitopes drive therapeutic immune responses to cancer· 2015 · 1,236 citations
5. Relationship of circulating tumor cells and Epstein–Barr virus DNA to progression‐free survival and overall survival in metastatic nasopharyngeal carcinoma patients· 2019 · 54 citations